[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Civil de Guadalajara\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":326},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,76,101,135,169,192,216,249,277,299],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100597571","phase-4-intestinal-preparation-in-colonoscopy-lactulose-vs-sodium-phosphate-100597571",false,"NCT07060222","Intestinal Preparation in Colonoscopy: Lactulose vs Sodium Phosphate.","Intestinal Preparation in Colonoscopy: Lactulose vs Sodium Phosphate, a Multicenter, Randomized, Double-Blind Comparative Clinical Trial.","Inclusion Criteria:\n\n* Indication for Scheduled Colonoscopy: Participants must have a valid clinical indication for undergoing a scheduled colonoscopy, such as part of a colorectal cancer screening program, evaluation of gastrointestinal symptoms, or follow-up of previously diagnosed colorectal conditions.\n* Ability to Provide Informed Consent: Participants must have the physical and mental capacity to understand the nature of the study and voluntarily provide informed consent to participate.\n\nExclusion Criteria:\n\n* History of Intestinal Obstruction: Participants with a known or suspected history of intestinal obstruction will be excluded due to the potential risks associated with the administration of bowel preparation agents.\n* Known Intolerance to Lactulose or Sodium Phosphate: Participants with a known intolerance to lactulose or sodium phosphate will be excluded due to the risk of severe adverse reactions.\n* Pregnancy and Lactation: Pregnant or breastfeeding women will be excluded due to the lack of safety data on bowel preparation agents in this population.\n* Interfering Clinical Conditions (Comorbidities): Participants with medical conditions that could interfere with study participation or affect the interpretation of results will be excluded, such as decompensated heart failure, chronic renal or liver disease, and a history of colonic resection.",true,"ALL","18 Years",{"count":20,"type":21},300,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","To compare intestinal preparation with Lactulose vs. Sodium Phosphate as the better agent for performing high-quality colonoscopies at the Civil Hospital Fray Antonio Alcalde and the Civil Hospital Juan I. Menchaca, both in Guadalajara, Mexico; as well as Hospital Santo Tomás in Panama City, Panama; and Hospital Gustavo Nelson Collado Ríos in Chitré, Panama; during the period from April 1, 2025, to November 30, 2025. The comparison will focus on colonoscopy quality, patient tolerance, satisfaction, and electrolyte changes, using the agents orally as part of the bowel preparation prior to the colonoscopy procedure.",[27],"Bowel Preparation for Colonoscopy",[29,30,31,32],"lactulose","Colonoscopy","sodium phosphate","bowel preparation","RECRUITING","2026-04-30",{"date":36,"type":37},"2026-05-05","ACTUAL",{"date":39,"type":37},"2025-09-20",{"date":41,"type":21},"2026-12-31",{"name":43,"class":44},"Hospital Civil de Guadalajara","OTHER",4,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100382905","the-invade-study-innominate-vein-approach-for-central-catheterization-in-difficult-to-cannulate-patients-100382905","NCT04265703","The INVADE Study: INnominate Vein Approach for Central Catheterization in Difficult to cannulatE Patients","Central Venous Access in Patients With Difficult Cannulation, A Randomized Controlled Trial","INVADE","Inclusion Criteria:\n\n* Patients who need central venous catheterization, and have respirophasic variation in cross-sectional area of jugular veins\n\nExclusion Criteria:\n\n* Less than 18 years-old\n\n  * Patients with previous failed attempts with non-ultrasound guided technique\n  * Non-resolved pneumothorax\u002Fhemothorax at enrollment\n  * Refusal to sign informed consent","80 Years",{"count":56,"type":21},315,[58],"NA","Most recent guidelines suggest central venous access must be performed with real-time ultrasound guidance, and the most recommended site for cannulation is internal jugular vein (IJV); however, it is recognized that evidence for other sites is, at present, limited. Besides, guidelines does not account for patients with small vein cross-sectional area and\u002For respirophasic collapse, which can make the procedure more difficult or even impossible. The investigators aim to compare three different insertion sites for central venous access, with real-time ultrasound guidance",[61],"Critical Illness",[63,64,65,66],"Central venous access","Ultrasound-guided catheterization","Innominate vein","Brachiocephalic vein","2026-03-10",{"date":69,"type":37},"2026-03-12",{"date":71,"type":37},"2024-02-27",{"date":73,"type":21},"2027-02-28",{"name":43,"class":44},1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":75},"100626476","curcumin-in-critically-ill-patients-with-sepsis-100626476","NCT07436130","Curcumin in Critically Ill Patients With Sepsis","Immunomodulatory Effect of Curcumin in Critically Ill Patients With Sepsis at the Antiguo Hospital Civil de Guadalajara \"Fray Antonio Alcalde\": A Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients older than 18 years of either sex.\n* Critically ill patients with a diagnosis of sepsis admitted to the Antiguo Hospital Civil de Guadalajara \"Fray Antonio Alcalde.\"\n* Patients receiving enteral nutrition.\n* Written informed consent signed by the patient or their legally authorized representative.\n\nExclusion Criteria:\n\n* Patients with a history of allergy or hypersensitivity to curcumin.\n* Patients with autoimmune diseases or severe immunosuppression.\n* Patients in a terminal condition with a life expectancy of less than 48 hours.\n* Patients with intolerance to enteral feeding, intestinal ischemia, intestinal obstruction, pancreatitis or short bowel syndrome.\n* Patients with acute liver failure or decompensated liver cirrhosis.\n* Patients with clinically significant active bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage, etc.).\n* Patients requiring therapeutic anticoagulation (warfarin, direct oral anticoagulants \\[DOACs\\], or full-dose heparin).\n* Patients receiving exclusively parenteral nutrition.\n* Pregnant or breastfeeding women.",{"count":84,"type":21},56,[58],"Sepsis is a life-threatening condition that occurs when the body's response to an infection becomes overwhelming and damages its own organs. It is one of the leading causes of death in critically ill (very sick) patients worldwide. Despite advances in antibiotics, intensive care, and life-support technologies, sepsis remains difficult to treat because much of the harm comes not only from the infection itself, but from an exaggerated and uncontrolled inflammatory response in the body. When a person develops sepsis, the immune system releases large amounts of inflammatory substances meant to fight infection. However, in many cases this response becomes excessive, leading to organ failure, prolonged stays in the intensive care unit (ICU), and increased risk of death. Current treatments focus mainly on controlling the infection and supporting failing organs, but there are limited therapies that directly help regulate this harmful immune overreaction. Curcumin is a natural compound found in turmeric, a spice commonly used in food. In laboratory studies and some clinical research, curcumin has shown anti-inflammatory and antioxidant properties. It appears to influence several pathways in the immune system that are involved in the inflammatory process. However, its potential benefits in patients with severe infections such as sepsis have not been fully studied in a rigorous clinical setting. The purpose of this clinical trial is to evaluate whether curcumin, when added to standard medical treatment, can help modulate (regulate) the immune response in critically ill patients with sepsis. This study will be conducted as a randomized, double-blind, placebo-controlled clinical trial at the Antiguo Hospital Civil de Guadalajara \"Fray Antonio Alcalde\" in Guadalajara, Mexico. \"Randomized\" means that participants will be assigned by chance to receive either curcumin or a placebo (a look-alike substance that contains no drug). \"Double-blind\" means that neither the patients nor the healthcare team will know who is receiving curcumin and who is receiving the placebo during the study. This design helps ensure that the results are objective and scientifically reliable. Participants in the study will continue to receive all standard treatments for sepsis, including antibiotics and intensive care support. The study will measure inflammatory markers in the blood, organ function, and important clinical outcomes such as the need for organ support and length of stay in the ICU. Safety will also be carefully monitored.\n\nHypothesis:\n\nThe investigators hypothesize that in critically ill patients with sepsis, the addition of curcumin to standard treatment will help regulate the excessive inflammatory response, leading to improved biological markers of inflammation and potentially better clinical outcomes, compared to standard treatment alone. If curcumin proves to be beneficial and safe in this population, it could represent an accessible and relatively low-cost complementary therapy to improve the management of sepsis. However, this study is necessary to determine scientifically whether these potential benefits are real and clinically meaningful. The ultimate goal of this research is to contribute new evidence that may improve the care and survival of patients suffering from one of the most severe and challenging conditions treated in intensive care medicine.",[88],"Sepsis",[88,90,61,91],"Curcumin","Immunomodulation","NOT_YET_RECRUITING","2026-02-20",{"date":95,"type":37},"2026-02-27",{"date":97,"type":21},"2026-03-01",{"date":99,"type":21},"2027-05-31",{"name":43,"class":44},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":108,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":75},"100597598","effects-of-oral-stimulation-performed-by-parents-to-improve-sucking-in-neonates-hospitalized-in-the-nicu-100597598","NCT07060573","Effects of Oral Stimulation Performed by Parents to Improve Sucking in Neonates Hospitalized in the NICU","Effects of Oral Stimulation Performed by Parents to Improve Sucking in Neonates Hospitalized in the NICU: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Neonates with corrected gestational age of 34 to 36 weeks\n* Clinically stable to receive oral stimulation\n* Informed consent obtained from parents or legal guardians\n\nExclusion Criteria:\n\n* Orofacial congenital malformations\n* Severe neuromuscular disease\n* Conditions contraindicating oral feeding","34 Weeks","36 Weeks",{"count":111,"type":21},32,[58],"This randomized clinical trial aims to evaluate the effectiveness of an oral stimulation program to improve sucking in preterm neonates hospitalized in the NICU. The study compares two groups: one receiving the intervention from a physiotherapist and the other from trained parents. The stimulation program includes 4 extraoral and 4 intraoral exercises applied once daily for 14 consecutive days. The primary outcome is improvement in the POFRAS score. Secondary outcomes include the time to exclusive oral feeding, nasogastric tube withdrawal, weight at discharge, hospital stay duration, and parental adherence. This study addresses the potential role of parent participation in neonatal rehabilitation in public hospitals with limited human resources.",[115,116],"Premature Infant","Sucking Behavior",[118,119,120,121,122,123,124,125,126],"Premature infant","sucking","oral stimulation","POFRAS","NICU","feeding","physiotherapy","Rehabilitation","parental involvement","2026-02-17",{"date":129,"type":37},"2026-02-19",{"date":131,"type":37},"2025-07-18",{"date":133,"type":21},"2027-02",{"name":43,"class":44},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":166,"leadSponsor":168,"locationsCount":75},"100624031","phase-4-low-dose-apixaban-added-to-standard-heparin-lock-versus-heparin-lock-alone-to-prevent-tunneled-hemodialysis-catheters-dysfunction-apicath-hd-100624031","NCT07404345","Low-Dose Apixaban Added to Standard Heparin Lock Versus Heparin Lock Alone to Prevent Tunneled Hemodialysis Catheters Dysfunction (APICATH-HD)","Efficacy of Low-Dose Apixaban Added to Standard Heparin Lock to Prevent Dysfunction of Tunneled Hemodialysis Catheters: A Randomized, PROBE, Parallel-Grupo Trial.","APICATH-HD","Inclusion Criteria:\n\n* Age ≥18 years with end-stage kidney disease (CKD stage 5) receiving maintenance hemodialysis or initiating hemodialysis.\n* Recently placed tunneled, double-lumen central venous hemodialysis catheter (tunneled CVC) in place for ≥8 days, with a post-placement radiograph confirming adequate tip position.\n* Permitted catheter insertion sites: right internal jugular, left internal jugular, right femoral, or left femoral vein.\n* Adequate initial catheter function, defined as ability to achieve the prescribed extracorporeal blood flow (suggested ≥300 mL\u002Fmin) for ≥8 days after catheter placement.\n* Conventional in-center hemodialysis schedule (2-3 sessions\u002Fweek) at the study unit, with expected ability to complete follow-up for up to 24 months.\n* Written informed consent provided.\n* Willingness to receive only the protocol-assigned antithrombotic prophylaxis and to avoid non-study systemic anticoagulants or antiplatelet agents during the study period.\n\nExclusion Criteria:\n\n* Non-tunneled hemodialysis catheter, subclavian catheter, or intracaval catheter placement not consistent with the protocol (e.g., catheter located in the SVC\u002FIVC without a subcutaneous tunnel, or catheter location\u002Fsite not permitted by the study).\n* Tunneled catheter placed \\\u003C8 days before randomization or radiographically confirmed catheter tip malposition at screening.\n* Active bleeding; active peptic ulcer disease; or clinically significant gastrointestinal bleeding within the past 30 days; uncorrectable INR \\>1.5; platelet count \\\u003C100,000\u002FµL.\n* High bleeding risk (HAS-BLED score \\>3) or major bleeding that is active or recent.\n* Known coagulopathy; history of heparin-induced thrombocytopenia (HIT); or allergy\u002Fhypersensitivity to heparin, citrate, or rt-PA (alteplase).\n* Severe hepatic impairment (e.g., Child-Pugh class C), clinically significant liver dysfunction that contraindicates DOAC therapy, or ongoing hemodialysis with regional citrate anticoagulation that cannot be modified per protocol.\n* Active catheter exit-site infection or bloodstream infection\u002Fbacteremia at the time of randomization.\n* Concomitant use of other systemic anticoagulants (e.g., warfarin, low-molecular-weight heparin, other DOACs) or high-intensity antiplatelet therapy (e.g., dual antiplatelet therapy).\n* Pregnancy or breastfeeding.\n* Women of childbearing potential who are unwilling to use a highly effective contraception method during the study and for 48 hours after the last dose of study medication.\n* Life expectancy \\\u003C6 months, current palliative\u002Fhospice care, or planned kidney transplant within ≤3 months.\n* Concurrent participation in another clinical trial that could interfere with the study interventions or outcomes.\n* Venography demonstrating significant venous stenosis involving the superior vena cava (SVC) or inferior vena cava (IVC).",{"count":144,"type":21},54,[24],"This randomized, single-center, PROBE trial evaluates whether adding low-dose apixaban (2.5 mg orally every 12 hours) to standard intraluminal heparin lock prolongs primary functional patency of tunneled hemodialysis catheters compared with standard heparin lock alone. Adult patients on hemodialysis with a recently implanted, functioning tunneled catheter (≥8 days) will be randomized 1:1 and followed up to 24 months (or until catheter loss). Primary outcome is time to first intervention for catheter dysfunction or definitive catheter loss. Secondary outcomes include primary-assisted and secondary patency, thrombotic dysfunction, rescue procedures, catheter-related infection, bleeding (ISTH), and mortality. Outcomes adjudication will be blinded.",[148,149,150],"Hemodialysis Access Failure","Kidney Disease, End-Stage","Hemodialysis Catheter",[152,153,154,155,156,157,158,159,160,161,162],"Hemodialysis","Tunneled central venous catheter","Catheter dysfunction","Catheter Failure","Catheter thrombosis","Apixaban","Heparin lock","End-stage kidney disease","Vascular access","Anticoagulation","PROBE trial","2026-02-12",{"date":127,"type":37},{"date":97,"type":21},{"date":167,"type":21},"2028-09-01",{"name":43,"class":44},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":4},"100610239","phase-2-trimethoprim-sulfamethoxazole-tmpsmx-prophylaxis-after-acute-kidney-injury-to-prevent-post-discharge-infections-100610239","NCT07224997","Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections","Inclusion Criteria\n\n* Age ≥18 years.\n* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.\n* Planned discharge to community\u002Frehabilitation with capacity for follow-up.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Known allergy to sulfonamides or TMP\u002FSMX.\n* Pregnancy or breastfeeding.\n* Severe hepatic disease (e.g., Child-Pugh C).\n* Severe cytopenia (e.g., ANC \\\u003C1.0×10⁹\u002FL or platelets \\\u003C50×10⁹\u002FL).\n* Baseline hyperkalemia (\\>5.5 mmol\u002FL) not correctable prior to randomization.\n* Concomitant medications with high-risk interactions not amenable to dose\u002Fmonitoring (per protocol).\n* Current systemic antimicrobial therapy planned for \\>14 days after discharge (prophylaxis not indicated).\n* Inability to adhere to study procedures or follow-up.",{"count":176,"type":21},120,[178],"PHASE2","Official Title\n\nTrimethoprim-Sulfamethoxazole (TMP\u002FSMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections: A Randomized, Double-Blind, Placebo-Controlled Trial\n\nBrief Summary\n\nAcute kidney injury (AKI) is commonly followed by infections after hospital discharge. This randomized, double-blind, placebo-controlled trial will test whether prophylactic TMP\u002FSMX reduces post-discharge infections in adults recently hospitalized with AKI. Participants will be randomized 1:1 to TMP\u002FSMX or matching placebo and followed for 6 months. The primary outcome is the proportion of participants who develop any infection within 90 days after discharge. Secondary outcomes include time to first infection, infection-related hospitalization, mortality, safety\u002Fadverse events, and healthcare utilization through 180 days.\n\nDetailed Description\n\nAdults discharged after an index hospitalization complicated by AKI are at elevated infection risk. This trial evaluates whether short-term TMP\u002FSMX prophylaxis reduces 90-day infections. After consent and eligibility confirmation near discharge, participants are randomized (1:1) to receive TMP\u002FSMX or matching placebo with double-blind masking (participant and outcome assessor). Dosing is standardized per protocol. We will ascertain infections via structured follow-up, medical record review, and adjudication by blinded assessors. Safety monitoring will capture adverse events (e.g., rash, cytopenias, hyperkalemia). Analyses follow intention-to-treat.\n\nStudy Design\n\n* Study Type: Interventional (Clinical Trial)\n* Primary Purpose: Prevention\n* Allocation: Randomized (1:1)\n* Intervention Model: Parallel Assignment\n* Masking: Double-blind (Participant, Outcomes Assessor)\n* Estimated Enrollment: 60 patients per group\n* Study Start Date: December 2025\n* Primary Completion Date (Anticipated): January 2027 (last patient reaches 90-day outcome)\n* Study Completion Date (Anticipated): July 2028 (last patient completes 180-day follow-up)\n\nArms \\& Interventions\n\nExperimental: TMP\u002FSMX\n\n* Intervention: Drug: Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) 160\u002F800 mg tablets every 48 hours\n* Dosing: One tablet by mouth, Trimethoprim-Sulfamethoxazole (TMP\u002FSMX) 160\u002F800 mg tablets every 48 hours, for 90 days post-discharge.\n* Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F\n\nPlacebo Comparator: Placebo\n\n* Intervention: Drug: Placebo (matching oral tablet)\n* Dosing: Matching schedule for 90 days post-discharge.\n\nConcomitant care: Allowed per treating clinician. Drug interactions and lab monitoring handled per protocol.\n\nOutcome Measures\n\nPrimary Outcome\n\n• Any infection within 90 days after discharge Time Frame: Day 0 (discharge) to Day 90 Measure: Proportion of participants with ≥1 infection, defined by clinical diagnosis requiring documentation (e.g., UTI, pneumonia, SSTI, bloodstream infection) and\u002For antimicrobial treatment initiation.\n\nSecondary Outcomes\n\n1. Time to first infection (days) within 90 days.\n2. Infection-related hospitalization within 90 and 180 days.\n3. All-cause mortality at 90 and 180 days.\n4. Emergency department visits or unplanned readmissions within 180 days.\n5. Antibiotic-related adverse events (rash, cytopenia, creatinine rise ≥0.3 mg\u002FdL, hyperkalemia ≥5.5 mmol\u002FL) through 180 days.\n6. C. difficile infection within 180 days.\n7. Recurrent AKI (KDIGO criteria) within 180 days.\n8. Medication adherence (pill counts and\u002For self-report) over 90 days.\n9. Major adverse kidney events over 90 days.\n\nEligibility Criteria\n\nInclusion Criteria\n\n* Age ≥18 years.\n* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.\n* Planned discharge to community\u002Frehabilitation with capacity for follow-up.\n* Ability to provide informed consent.\n\nExclusion Criteria\n\n* Known allergy to sulfonamides or TMP\u002FSMX.\n* Pregnancy or breastfeeding.\n* Severe hepatic disease (e.g., Child-Pugh C).\n* Severe cytopenia (e.g., ANC \\\u003C1.0×10⁹\u002FL or platelets \\\u003C50×10⁹\u002FL).\n* Baseline hyperkalemia (\\>5.5 mmol\u002FL) not correctable prior to randomization.\n* Concomitant medications with high-risk interactions not amenable to dose\u002Fmonitoring (per protocol).\n* Current systemic antimicrobial therapy planned for \\>14 days after discharge (prophylaxis not indicated).\n* Inability to adhere to study procedures or follow-up.\n\nContacts\u002FLocations\n\n* Lead Sponsor \u002F Responsible Party: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología\n* Principal Investigator: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología, 3313299609\n* Study Locations: Hospital Civil de Guadalajara, servicio de Nefrología, Hospital 278, colonia el Retiro. Guadalajara. Jalisco.\n\nEthics and Oversight\n\n* Conducted in accordance with the Declaration of Helsinki and ICH-GCP.\n* IRB\u002FEthics approval: Comité de etica en investigacion, Protocol CEI 214\u002F25, Approval : October 16, 2025.\n* Written informed consent obtained from all participants prior to any study procedures.\n* Data",[181,182,183],"Acute Kidney Injuries","Acute Kidney Disease","Acute Kidney Injury (AKI)","2025-11-02",{"date":186,"type":37},"2025-11-05",{"date":188,"type":21},"2025-12-01",{"date":190,"type":21},"2027-07-01",{"name":43,"class":44},{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":201,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":213,"leadSponsor":215,"locationsCount":75},"100608751","evaluation-of-the-diaphragmatic-index-before-and-after-a-pulmonary-rehabilitation-program-in-patients-with-interstitial-lung-diseases-and-its-impact-on-quality-of-life-100608751","NCT07205627","Evaluation of the Diaphragmatic Index Before and After a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Diseases and Its Impact on Quality of Life","Evaluation of the Diaphragmatic Index Before and After a Pulmonary Rehabilitation Program in Patients With Interstitial Lung Diseases and Its Impact on Quality of Life During the Period July-December 2025 at AHCGFAA","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Confirmed diagnosis of interstitial lung disease (ILD) by pulmonology and imaging criteria.\n* Clinically stable for at least 4 weeks prior to enrollment (no exacerbations or hospitalizations).\n* Able to perform pulmonary rehabilitation and functional tests safely, as determined by medical evaluation.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Acute exacerbation of ILD or respiratory infection within the last 4 weeks.\n* Severe comorbidities limiting participation (e.g., unstable cardiac disease, uncontrolled hypertension, recent myocardial infarction \\\u003C 3 months).\n* Advanced neuromuscular disease or musculoskeletal limitation that prevents exercise training.\n* Cognitive impairment or psychiatric condition interfering with protocol adherence.\n* Pregnancy or breastfeeding",{"count":200,"type":21},20,[58],"Interstitial lung diseases cause scarring and stiffness of the lungs, leading to impaired breathing and reduced quality of life. The diaphragm, the main respiratory muscle, may become weakened in these patients. Pulmonary rehabilitation is a comprehensive program that includes exercise, education, and support to improve physical capacity and overall well-being.\n\nThis study will evaluate whether an eight-week pulmonary rehabilitation program improves the diaphragmatic index (measured by ultrasound), quality of life, exercise tolerance (through functional tests), muscle strength, and dyspnea perception in patients with interstitial lung diseases.\n\nParticipants will be recruited at the Antiguo Hospital Civil de Guadalajara \"Fray Antonio Alcalde\" between July and December 2025. The findings will provide new insights into the impact of pulmonary rehabilitation on diaphragmatic function and contribute scientific evidence to optimize the treatment of these conditions.",[204],"Lung Disease Interstitial Diffuse",[206,207,208],"pulmonary rehabilitation","intersticial lung disease","quality of life","2025-09-25",{"date":211,"type":37},"2025-10-03",{"date":209,"type":21},{"date":214,"type":21},"2025-12-30",{"name":43,"class":44},{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":234,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":75},"100608222","bimodal-vs-unimodal-high-intensity-pulsed-electromagnetic-field-therapy-in-older-adults-with-knee-osteoarthritis-100608222","NCT07198750","\"Bimodal vs Unimodal High-Intensity Pulsed Electromagnetic Field Therapy in Older Adults With Knee Osteoarthritis\"","Effect of High-Intensity Pulsed Electromagnetic Field Therapy as a Bimodal Intervention for Analgesia and Strengthening in Older Adults With Knee Osteoarthritis: A Randomized Double-Blind Controlled Clinical Trial","HIPEMF-OAK","Inclusion Criteria:\n\n* Age ≥ 60\n* Clinical and radiological diagnosis of knee OA grade I-IV\n* Pain ≥ 3 on Numeric Analog Scale for \\>6 months\n* Can walk (with\u002Fwithout aid)\n* Cognitive ability to follow instructions\n* Signed informed consent\n* Availability for 9 treatment sessions and home exercise Exclusion Criteria\n* Prior total knee arthroplasty (unilateral or bilateral)\n* Neurological disorders affecting motor function or cognition (e.g., Parkinson's disease, stroke, moderate to severe dementia)\n* Active inflammatory rheumatic diseases (e.g., rheumatoid arthritis, lupus)\n* Presence of pacemakers, implantable defibrillators, or metallic implants near the treatment area\n* Current use of other physical therapy modalities for pain (e.g., electrotherapy, ultrasound, TENS) outside the study protocol\n* Participation in another clinical trial within the past 3 months\n* Current use of NSAIDs or systemic\u002Flocal corticosteroids (including intra-articular injections)\n* Open wounds or active infections at the treatment site\n* Decompensated cardiac conditions or medical contraindication to exercise\n* Vestibular disorders that affect balance and interfere with functional assessments\n* Uncorrected visual impairment interfering with gait or balance (visual acuity worse than 20\u002F60 in the better eye, assessed by Snellen chart)\n\nWithdrawal Criteria:\n\n* Participants who complete fewer than 7 out of the 9 planned intervention sessions (i.e., less than 80% adherence)\n* Occurrence of serious adverse events related to the intervention that contraindicate continuation\n* Repeated non-compliance with the home exercise program, documented in at least two consecutive weekly follow-up reports\n* Voluntary withdrawal of consent at any time during the study","60 Years",{"count":226,"type":21},64,[58],"This randomized, double-blind clinical trial aims to evaluate the effect of high-intensity pulsed electromagnetic field therapy (HI-PEMF) applied either exclusively on the knee joint or bimodally on the knee and quadriceps, in older adults with knee osteoarthritis. Both groups will also receive a structured home-based exercise program. The primary outcome is pain reduction, and secondary outcomes include functional performance.",[230,231,232,233],"Knee Osteoarthritis","Osteoarthritis","Osteo Arthritis of the Knee","Gonarthrosis",[235,236,237,230,233,238,239,240],"High-Intensity Pulsed Electromagnetic Fields","HI-PEMF","Super Inductive System","Geriatric Rehabilitation","Chronic Pain","Functional Mobility","2025-09-22",{"date":243,"type":37},"2025-09-30",{"date":245,"type":37},"2025-09-15",{"date":247,"type":21},"2026-04-15",{"name":43,"class":44},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":260,"phases":4,"briefSummary":261,"conditions":262,"keywords":266,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":75},"100527492","reverse-trigger-phenotypification-and-response-to-ventilatory-adjustments-100527492","NCT06148467","Reverse Trigger Phenotypification and Response to Ventilatory Adjustments","Incidence of Reverse Trigger Phenotypes and Response to Ventilatory Adjustments in Patients With ARDS","RT-CHASERS","Inclusion Criteria:\n\n* Diagnosis of ARDS according to the Berlin criteria and added New Global Definition 2023\n* Mechanical ventilation\n\nExclusion Criteria:\n\n* \\\u003C18 years\n* Tracheostomy status\n* Pneumothorax\n* Tube thoracostomy with air leaks","90 Years",{"count":259,"type":21},130,"OBSERVATIONAL","The goal of this prospective observational study is to describe the incidence of reverse trigger (RT) in mechanically ventilated patients with diagnosis of acute respiratory distress syndrome (ARDS).\n\nThe main questions it aims to answer are:\n\n* Real incidence of RT based on continuous monitoring\n* The response to mechanical ventilatiory adjustments Participants will be included as soon as neuromuscular blockers (NMB)\u002Fsedation is stopped or in case of spontaneous respiratory efforts detection, whatever happens first. Continuous monitoring will be performed by esophageal manometry until switch to a pressure support (spontaneous) mode, restart of deep sedation\u002Fneuromuscular blockers by medical indication, or death.\n\nIn order to allow detection of possible RT in patients with ongoing sedation\u002FNMB, mechanical ventilator waveforms will be screened every 1-2 hours by investigators and critical care physicians with at least 1 year of specific training in detection of dyssynchronies.",[263,264,265],"Reverse Trigger","Acute Respiratory Distress Syndrome","Mechanical Ventilation",[267,264,268,265],"Reverse trigger","Dyssynchony","2025-03-15",{"date":271,"type":37},"2025-03-18",{"date":273,"type":37},"2023-11-17",{"date":275,"type":21},"2026-02-01",{"name":43,"class":44},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":75},"100379527","early-use-of-airway-pressure-release-ventilation-aprv-in-ards-100379527","NCT04221737","Early Use of Airway Pressure Release Ventilation (APRV) in ARDS","Early Use of Airway Pressure Release Ventilation (APRV) in Patients With Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Acute respiratory distress syndrome, according to the Berlin definition of ARDS, with adjusted pO2\u002FFiO2 for altitude \\\u003C300, and less than 48 h of endotracheal mechanical ventilation\n\nExclusion Criteria:\n\n* Pregnancy\n* Less than 18 years-old\n* Expected duration of mechanical ventilation less than 48 h\n* Preexisting conditions with an expected 3-month mortality exceeding 50%\n* Concurrent chemotherapy\n* Confirmed intracranial hypertension\n* Catastrophic cranial trauma or neuromuscular disorders that are known to prolong mechanical ventilation\n* Pneumothorax at enrollment (resolved or not)\n* Do-not-resuscitate order",{"count":285,"type":21},150,[58],"Airway pressure release ventilation (APRV) is a time-cycled, pressure controlled, intermittent mandatory ventilation mode with extreme inverse I:E ratios. Currently it is considered as a non-conventional ventilatory mode. The investigators aim to compare APRV with conventional mechanical ventilation (MV) in patients with acute respiratory distress syndrome (ARDS).",[264],[264,290,265,291],"Acute Lung Injury","APRV",{"date":293,"type":37},"2025-03-19",{"date":295,"type":37},"2017-07-15",{"date":297,"type":21},"2026-01",{"name":43,"class":44},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":303,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":325},"100567312","phase-4-bowel-preparation-in-colonoscopy-lactulose-vs-polyethyleneglycol-randomized-double-blind-comparative-clinical-trial-multicenter-study-100567312","NCT06666556","Bowel Preparation in Colonoscopy: Lactulose Vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study.","* Inclusion Criteria:\n* Patients with indication for colonoscopy in our coloproctology service\n* Both women and men\n* Patients within an age range of 18-79 years\n* Patients who agree having a colonoscopy and who sign the informed consent to participate in the protocol\n\nExclusion Criteria:\n\n* Patients under 18 or over 80 years old\n* All patients that won´t like to participate in the protocol or won´t sign the informed consent\n* Pregnant women\n* Patients with a medical record of colonic resection, ostomy status, severe cardiopulmonary and renal diseases, major psychiatric disorders, therapeutic colonoscopy or any contraindications for colonoscopy\n* Non compliance with the colonic preparation regimen\n* Active bleeding during the procedure\n* Patients with a known diagnosis of colorectal cancer","79 Years",{"count":20,"type":21},[24],"The goal of this clinical trial it is to bowel the instestinal preparation with lactulose vs poliethylenglicol as better agent to have a quality colonoscopy and demostrate that lactulose is most efective, has a good tolerance and the patient would have a better satisfaction, so the question is:\n\nwich is the eficancy of lactulose in comparision with thepoliethylenglycol in the intestinal preparation for the colonoscopy?",[310],"Colorectal Cancer Screening",[312,313,314,315,316,29],"colorectal","colorectal cancer","colorectal cancer screening","colonoscopy","polyethylenglycol","2024-10-29",{"date":319,"type":37},"2024-10-30",{"date":321,"type":37},"2024-07-20",{"date":323,"type":21},"2025-08-01",{"name":43,"class":44},3,""]